Dabrafenib is a targeted therapy drug primarily used for the treatment of malignancies such as BRAF V600 mutation-positive melanoma and non-small cell lung cancer. Its specifications and prices vary depending on the manufacturer. Patients also need to pay attention to the administration method and related contraindications when using it. This article details information about dabrafenib from three aspects: specification types, price differences, and medication precautions, to help patients and their families better understand this drug.
How many specifications does Dabrafenib have?
The specifications of dabrafenib are mainly divided by dosage and formulation. Different specifications cater to different treatment needs and dose adjustments.
Capsule Formulation
The most common formulation of dabrafenib is capsules, mainly available in two strengths: 50mg and 75mg. The 50mg capsules are dark red and imprinted with "GSTEW50mg". The 75mg capsules are dark pink and imprinted with "GSLHF75mg". The contents of both capsule strengths are white to off-white powder.
Oral Suspension
Besides capsules, dabrafenib is also available as an oral suspension for patients who cannot swallow capsules. The strength of the oral suspension is usually similar to the capsules, but the specific dose should be adjusted according to the doctor's instructions.
Packaging Specifications
Dabrafenib is typically packaged as 120 capsules per box, suitable for long-term treatment needs. Both the 50mg and 75mg capsules can be used for dose adjustment, allowing doctors flexibility in prescribing based on the patient's condition.
Dabrafenib has various specifications, allowing patients to choose the appropriate formulation and dosage based on their needs and doctor's advice.
How much do different specifications of Dabrafenib cost?
The price of dabrafenib varies depending on factors such as specification, manufacturer, and regional policies. Below is common pricing information available on the market.
Branded Drug Price
The price of the branded drug dabrafenib (trade name: TAFINLAR) manufactured by Novartis (Switzerland) is higher. The price for both the 50mg*120 capsules/box and 75mg*120 capsules/box specifications is approximately 1869 USD. Branded drugs are relatively more expensive due to high R&D costs, but their quality and efficacy are guaranteed.
Generic Drug Price
Generic drugs have a price advantage. The generic drug from Bear Pharm (Laos) comes in a specification of 75mg*120 capsules/box, paired with trametinib 2mg*30 capsules/box, at a price of approximately 600 USD per set. The generic drug from Lucius has a specification of 75mg*120 capsules/box, priced at approximately 251 USD. Generics are suitable for patients with limited budgets, but attention must be paid to the drug source and quality when purchasing.
The price of dabrafenib is influenced by factors such as drug specification, manufacturer, and regional medical insurance policies. Patients can choose the appropriate drug based on their financial situation and treatment needs.
Precautions for Dabrafenib
When using dabrafenib, attention should be paid to the administration method, adverse reactions, and contraindications for special populations.
Administration Method
Dabrafenib should be taken 1 hour before or 2 hours after a meal, swallowed whole with warm water, and must not be opened or crushed. Take twice daily, approximately 12 hours apart, and the daily administration time should be fixed. When used in combination with trametinib, the drugs should be taken concurrently under the guidance of a physician.
Adverse Reactions
Common adverse reactions of dabrafenib include fever, rash, headache, and arthralgia. Serious adverse reactions may involve cardiac dysfunction, liver injury, etc. Relevant indicators need regular monitoring during treatment, and medical attention should be sought promptly if discomfort occurs.
Contraindications for Special Populations
Dabrafenib is contraindicated in pregnant women, breastfeeding women, and children. Elderly patients and those with hepatic or renal impairment should use it cautiously, with dose adjustments if necessary. Concomitant use with strong inhibitors or inducers of CYP2C8 or CYP3A4 should be avoided during treatment to prevent drug interactions.
The use of dabrafenib must strictly follow medical advice, monitor for adverse reactions, and be used cautiously in special populations.
